Bristol-Myers Squibb news
The WiseView Research desk's stories that name Bristol-Myers Squibb, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The BMY page →
- HeadlineBristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It Matters
- HeadlineShould You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
- HeadlineBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- HeadlineBristol Myers Squibb: Bargain Buy or Value Trap?
- HeadlineBristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
- HeadlineIzalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
- Week aheadWeek Ahead: Fed Decision, GDP, PCE Inflation and Peak Earnings Week
The Fed's rate decision, Q3 GDP and core PCE inflation headline a week in which 178 S&P 500 companies report earnings.
- HeadlineShould You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?
- HeadlineBristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
- HeadlineBMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?
- HeadlinePathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
- HeadlineTempus Expands Strategic Collaboration with Bristol Myers Squibb
- HeadlinePathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions
- HeadlineBristol Myers, SystImmune drug cuts breast cancer progression risk in study
- HeadlineBristol Myers Squibb vs. Novo Nordisk: Stable Scale vs.
- HeadlineBristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
- HeadlineCan BMY Navigate Generic Challenges Across Its Key Drug Portfolio?
- HeadlineBristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings
- HeadlineBristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
- HeadlineBristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
- HeadlineBristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
- HeadlineBMY Reports Mixed Phase III Trial Results, Stock Down
- HeadlineWhy Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
- HeadlineBristol Myers falls 3% despite positive cancer drug trial results
- HeadlineBMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?
- HeadlineBristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETs
- HeadlineBristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
- HeadlineWill Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
- HeadlineBristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs.
- HeadlineBristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An Opportunity
- HeadlineCan Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
- HeadlineHere's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
- HeadlineBMY or ARGX: Which Is the Better Value Stock Right Now?
- HeadlineAre Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?
- HeadlineBristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy?
- HeadlineWill Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
- HeadlineBristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
- HeadlineU.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
- HeadlineBristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow Metric
- HeadlineInvestors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
- CongressTommy Tuberville sold $1,001 - $15,000 of BMY
- CongressMike Kelly sold $15,001 - $50,000 of BMY
- CongressJulie Johnson sold $1,001 - $15,000 of BMY
- CongressJulia Letlow sold $1,001 - $15,000 of BMY
- CongressGilbert Cisneros bought $1,001 - $15,000 of BMY
- CongressGilbert Cisneros bought $1,001 - $15,000 of BMY
- CongressJulie Johnson sold $1,001 - $15,000 of BMY
- CongressGilbert Cisneros sold $1,001 - $15,000 of BMY
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.